As the country is hoping for lower drug prices, more affordable care, and solutions to the opioid epidemic sweeping the nation, Big Pharma is making backroom deals with Congress to fund a $4 billion bailout. Using the opioid package as its vehicle, Big Pharma is pushing to lower drug makers’ liability in the doughnut […]
Apparently, when it comes to out-of-control drug prices, everyone’s to blame but drug makers themselves, who are solely responsible for setting the list prices of the medications we need. Now, Big Pharma is pointing fingers at hospitals, accusing them of price gouging patients – despite the fact that big drug makers have increased the prices […]
Big Pharma is always eager to play the blame game – attempting to divert attention away from tactics that price-gouge vulnerable patients. But these gratuitous attacks conveniently ignore the facts. To keep Big Pharma and its backers in check, CSRxP is starting a new blog series called “Second Opinion” to set the record straight on […]
“While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point.”
CSRxP Calls for Action on CREATES Act The Campaign for Sustainable Rx Pricing released this statement from spokesman Will Holley on today’s House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law hearing on Antitrust Concerns and the FDA Approval Process: “Out-of-control prescription drug prices are an epidemic that harm all Americans. They affect not […]
Read “The Competition Prescription,” a new white paper by Avik Roy, President of Foundation for Research on Equal Opportunity on how federal policy has artificially driven up the cost of prescription drugs, and market-based reforms to bring prices down.
“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety.”
“The addition of the well-respected Society of General Internal Medicine is crucial as CSRxP continues to build a broad partnership of leaders from every corner of healthcare that are dedicated to fixing the broken prescription drug market,” said CSRxP Executive Director John Rother.
“Patients with chronic conditions, such as Hepatitis C, benefit immensely when breakthrough, life-changing drugs provide a cure where none existed before. But when states are driven to create access limitations to that same drug for their Medicaid populations, we have to acknowledge something is not quite right here.”
“We are glad to see that the court rejected AstraZeneca’s effort to abuse the Orphan Drug Act and restrict generic competitors to Crestor,” said John Rother. “Additional competition in the prescription drug market—including generic options—is crucial to lowering prescription drug prices and providing patients with more affordable choices.”